Compare VEEE & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEEE | CDIO |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.1M |
| IPO Year | 2021 | 2021 |
| Metric | VEEE | CDIO |
|---|---|---|
| Price | $9.11 | $1.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 24.8K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,819,130.00 | $14,825.00 |
| Revenue This Year | $1.22 | $168,534.06 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.99 | N/A |
| 52 Week Low | $8.10 | $0.97 |
| 52 Week High | $174,752.84 | $7.91 |
| Indicator | VEEE | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 36.24 |
| Support Level | $8.34 | $1.44 |
| Resistance Level | $22.85 | $2.17 |
| Average True Range (ATR) | 0.93 | 0.14 |
| MACD | 162.00 | -0.03 |
| Stochastic Oscillator | 24.15 | 14.71 |
Twin Vee PowerCats Co is a designer, manufacturer, and marketer of recreational and commercial power boats to use for fishing, diving and water skiing, and commercial activities including transportation, eco-tours, fishing, and diving expeditions. The company offers various boat models, including Twin Vee 400 GFX2 CC, Twin Vee 280 GFX2 CC, and Twin Vee 260 Center Console STX, among others. Its products are marketed under two brands, Twin Vee for its catamarans, or dual-hull vessels, and Aquasport for its V-hull boats. The company sells its boats through a network of independent boat dealers across North America, the Caribbean, and Central America who resell the boats to the end user, Twin Vee customers.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.